Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCARB1 | Q8WTV0 | 8/20 | 0.67 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.56 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.56 |
| ▸ | PTGDR2 | Q9Y5Y4 | 5/20 | 0.46 |
| ▸ | SIRT2 | Q8IXJ6 | 3/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4190055 | 0.81 | SCARB1 (0.72) | SCARB1PTGS1PTGS2PTGDR2SIRT2 | |
| SCHEMBL4205583 | 0.81 | SCARB1 (0.72) | SCARB1PTGS1PTGS2PTGDR2SIRT2 | |
| SCHEMBL13746688 | 0.80 | SCARB1 (1.00) | SCARB1PTGS1PTGS2PTGDR2SIRT2 | |
| SCHEMBL4188291 | 0.77 | SCARB1 (0.72) | SCARB1PTGS1PTGS2PTGDR2SIRT2 | |
| SCHEMBL4199253 | 0.76 | SCARB1 (0.66) | SCARB1PTGS1PTGS2PTGDR2SIRT2 | |
| SCHEMBL4200984 | 0.76 | SCARB1 (0.68) | SCARB1PTGS1PTGS2PTGDR2 | |
| SCHEMBL13746696 | 0.75 | SCARB1 (1.00) | SCARB1PTGS1PTGS2 | |
| SCHEMBL4202035 | 0.74 | SCARB1 (0.66) | SCARB1PTGS1PTGS2PTGDR2 | |
| SCHEMBL4194010 | 0.74 | SCARB1 (0.60) | SCARB1PTGS1PTGS2PTGDR2SIRT2 | |
| SCHEMBL4192942 | 0.74 | SCARB1 (1.00) | SCARB1PTGS1PTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2009103022-A1 | DERIVATIVES OF SUBSTITUTED FUSED RING CYCLOINDOLES AND METHODS OF THEIR USE | ITHERX PHARMACEUTICALS, INC. (US) | 2009-08-20 | — | — | WO | disclosed |